Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Warfarin = Aspirin for Stroke

Warfarin = Aspirin for Stroke Because 60% of patients who have an ischemic stroke have a recurrence within 2 years, physicians generally prescribe an anticoagulant, the most common being aspirin or warfarin. A large head-to-head study, reported at the May meeting of the American Academy of Neurology (AAN), shows that the two drugs perform equally well in reducing recurrence. However, because warfarin is more difficult to prescribe and more expensive, the findings will result in the gradual abandonment of warfarin for these patients, said Vladimir Hachinski, MD, of the University of Western Ontario, London. Funded by the National Institute of Neurological Disorders and Stroke, the 47-center Warfarin-Aspirin Recurrent Stroke Study (WARSS) followed up 2206 patients for 2 years. Within 30 days of their first stroke, patients were randomized to receive aspirin (325 mg/d) or warfarin (in dosages sufficient to maintain an International Normalized Ratio of 1.4 to 2.8). Patients with cardioembolic strokes were excluded from the study because anticoagulants increase the risk of hemorrhage. Both drugs reduced the risk of stroke equally, and both had the same rate of serious complications, less than 2%. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Warfarin = Aspirin for Stroke

JAMA , Volume 285 (23) – Jun 20, 2001

Warfarin = Aspirin for Stroke

Abstract

Because 60% of patients who have an ischemic stroke have a recurrence within 2 years, physicians generally prescribe an anticoagulant, the most common being aspirin or warfarin. A large head-to-head study, reported at the May meeting of the American Academy of Neurology (AAN), shows that the two drugs perform equally well in reducing recurrence. However, because warfarin is more difficult to prescribe and more expensive, the findings will result in the gradual abandonment of warfarin for...
Loading next page...
 
/lp/american-medical-association/warfarin-aspirin-for-stroke-MPIaGtm0HL

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 2001 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.285.23.2966
Publisher site
See Article on Publisher Site

Abstract

Because 60% of patients who have an ischemic stroke have a recurrence within 2 years, physicians generally prescribe an anticoagulant, the most common being aspirin or warfarin. A large head-to-head study, reported at the May meeting of the American Academy of Neurology (AAN), shows that the two drugs perform equally well in reducing recurrence. However, because warfarin is more difficult to prescribe and more expensive, the findings will result in the gradual abandonment of warfarin for these patients, said Vladimir Hachinski, MD, of the University of Western Ontario, London. Funded by the National Institute of Neurological Disorders and Stroke, the 47-center Warfarin-Aspirin Recurrent Stroke Study (WARSS) followed up 2206 patients for 2 years. Within 30 days of their first stroke, patients were randomized to receive aspirin (325 mg/d) or warfarin (in dosages sufficient to maintain an International Normalized Ratio of 1.4 to 2.8). Patients with cardioembolic strokes were excluded from the study because anticoagulants increase the risk of hemorrhage. Both drugs reduced the risk of stroke equally, and both had the same rate of serious complications, less than 2%.

Journal

JAMAAmerican Medical Association

Published: Jun 20, 2001

Keywords: aspirin,warfarin,cerebrovascular accident,ischemic stroke

There are no references for this article.